A rumor regarding Cytokinetics (CYTK) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, ...

Morgan Stanley has upgraded Cytokinetics (CYTK) to overweight from equal weight while lowering its price target. Read more ...

Fintel reports that on February 13, 2025, Morgan Stanley upgraded their outlook for Cytokinetics (NasdaqGS:CYTK) from ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Morgan Stanley analyst Jeffrey Hung upgraded Cytokinetics (CYTK) to Overweight from Equal Weight with a price target of $67, down from $70. The ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN ...

Cytokinetics (NASDAQ:CYTK) quickly rose 7.5% amid some renewed takeover speculation. There's some speculation that the company has had some fresh bid interest, according to traders, who cited a ...

Cytokinetics has a 1-year low of $42.72 and a 1-year high of $81.36. The business’s fifty day moving average price is $48.32 and its two-hundred day moving average price is $52.34. Insider ...

Citi launched its coverage of Cytokinetics (NASDAQ:CYTK) with a Buy recommendation, noting that the cardiac drug developer’s recent selloff is overdone given that its lead asset, aficamten ...

Cytokinetics' flagship program, aficamten, is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle.